Monogenetic Disorders Testing Market

According to Mendel's Laws, the monogenetic disorders are inherited because of a single defective gene on the autosomes. The monogenic disorders are caused by single mutated gene which can be present on single or both chromosomes. Females and males are equally affected by this disorder due to the conditions on the autosomes. Some of the tests are available for the mainstream of the common monogenic disorders such as Cystic fibrosis, sickle cell anemia, SCID, Tay-sachs disease, polycystic kidney disorder, Gaucher's disease, Huntington's disease, neurofibromatosis, thalassaemia and familial hypercholesterolemia. There are several test performed to treat with the monogenic disorders such as diagnostic testing, carrier testing, predictive & pre-symptomatic testing, prenatal testing and new-born screening.

Monogenetic Disorders Testing Market contains market size and forecasts of Monogenetic Disorders Testing in Global, including the following market information:

• Global Monogenetic Disorders Testing Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

The global Monogenetic Disorders Testing market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Carrier Testing Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Monogenetic Disorders Testing include Celera Group, Abbott, Thermo Fisher Scientific, ELITech Group, Quest, AutoGenomics, PerkinElmer, Roche and Bio-Rad and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Monogenetic Disorders Testing companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Monogenetic Disorders Testing Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Monogenetic Disorders Testing Market Segment Percentages, by Type, 2021 (%)

• Carrier Testing
• Diagnostic Testing
• New-Born Screening
• Predictive & Pre-Symptomatic Testing
• Prenatal Testing
• Others

Global Monogenetic Disorders Testing Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Monogenetic Disorders Testing Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Specialized Clinics
• Ambulatory Surgical Centers

Global Monogenetic Disorders Testing Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Monogenetic Disorders Testing Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Monogenetic Disorders Testing revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Monogenetic Disorders Testing revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Celera Group
• Abbott
• Thermo Fisher Scientific
• ELITech Group
• Quest
• AutoGenomics
• PerkinElmer
• Roche
• Bio-Rad
• Transgenomic